{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-25-000038","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2025-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.056492+00:00","generated_at":"2026-05-20T07:40:53.922738+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Supernus receives Paragraph IV ANDA filings for Qelbree; patents expire 2029-2035","bullets":["Received Paragraph IV notice letters for ANDA of viloxazine ER capsules 100, 150, 200 mg.","Six Orange Book patents listed; three expire Sept 2029, two Feb 2033, one April 2035.","Company intends to vigorously enforce its Qelbree intellectual property rights.","Currently reviewing details of the ANDA filings from third parties."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-25-000038","json":"https://secwatch.observer/filing/0001356576-25-000038.json","markdown":"https://secwatch.observer/filing/0001356576-25-000038.md","text":"https://secwatch.observer/filing/0001356576-25-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000038/0001356576-25-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000038/supn-20250522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T07:40:53.922738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}